Preclinical Contract Research Services

ImQuest BioSciences is a preclinical contract research and development company that provides service to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of infectious disease, cancer and inflammatory disease.

As part of our ImQuest SUCCESS platform, we provide expert laboratory research services to define the efficacy and toxicity of pharmaceutical products and specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines.

We have expertise in services for antiviral, antimicrobial, and anticancer product development, in vitro toxicology assessment and pharmaceutical product characterization and formulation.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. We understand that each product and each client is unique and we strive to provide effective solutions. Learn More.

What's New

  • Lessons from HIV Research for Prevention: How to Prevent Mucosal Transmission of HIV

    ImQuest scientists have intense interest and capability to develop products to prevent the transmission of herpes simplex virus, human papillomavirus, bacterial and fungal vaginosis organisms, Chlamydia, as well as hepatitis B and C viruses.

    Read More


  • Society of Toxicology -- Annual Meeting

    March 12-16, 2017
    Baltimore, MD
  • International Conference on Antiviral Research

    May 21-25, 2017

Meet the Team

Robert W. Buckheit, Jr., Ph.D.

President and CSO

Dr. Buckheit received a B.S. in Biology from Lehigh University in 1982, a Ph.D. in Microbiology and Immunology from Duke University in 1986, and

Read More